Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms

Cancer Letters

Volumn 306, Issue 2, 2011, Pages 223-229

  Mueller, Sabine ^a,b   Yang, Xiaodong ^a   Sottero, Theo L ^a   Gragg, Ashley ^a   Prasad, Gautam ^a   Polley, Mei Yin ^c   Weiss, William A ^a,b   Matthay, Katherine K ^b   Davidoff, Andrew M ^d   DuBois, Steven G ^b   Haas Kogan, Daphne A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

DNA repair; Metastatic neuroblastoma; Radiation; Vorinostat

Indexed keywords

HISTONE H2AX; HISTONE H4; KU 86 PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD51 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DISEASE MODEL; DNA REPAIR; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR VOLUME; WEIGHT REDUCTION;

ACETYLATION; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DNA REPAIR ENZYMES; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GAMMA RAYS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; NEUROBLASTOMA; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

MURINAE;

EID: 79955484293     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.010     Document Type: Article

References (21)

1. Matthay K.K., Yanik G., Messina J., Quach A., Huberty J., Cheng S.C., Veatch J., Goldsby R., Brophy P., Kersun L.S., Hawkins R.A., Maris J.M. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J. Clin. Oncol. 2007, 25:1054-1060.
2. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 2006, 5:1967-1974.
3. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:223-229.
4. Entin-Meer M., Rephaeli A., Yang X., Nudelman A., VandenBerg S.R., Haas-Kogan D.A. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol. Cancer Ther. 2005, 4:1952-1961.
5. Entin-Meer M., Yang X., VandenBerg S.R., Lamborn K.R., Nudelman A., Rephaeli A., Haas-Kogan D.A. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol. 2007, 9:82-88.
6. Folkvord S., Ree A.H., Furre T., Halvorsen T., Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:546-552.
7. Baschnagel A., Russo A., Burgan W.E., Carter D., Beam K., Palmieri D., Steeg P.S., Tofilon P., Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol. Cancer Ther. 2009, 8:1589-1595.
8. A.H. Ree, S. Dueland, S. Folkvord, K.H. Hole, T. Seierstad, M. Johansen, T.W. Abrahamsen, K. Flatmark, Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study, Lancet Oncol. 11, 459-464.
9. Taki T., Ohnishi T., Yamamoto A., Hiraga S., Arita N., Izumoto S., Hayakawa T., Morita T. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem. Biophys. Res. Commun. 1996, 223:434-438.
10. Dickson P.V., Hamner B., Ng C.Y., Hall M.M., Zhou J., Hargrove P.W., McCarville M.B., Davidoff A.M. In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J. Pediatr. Surg. 2007, 42:1172-1179.
11. Lutz W., Stohr M., Schurmann J., Wenzel A., Lohr A., Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996, 13:803-812.
12. Franken N.A., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1:2315-2319.
13. Rosati S.F., Williams R.F., Nunnally L.C., McGee M.C., Sims T.L., Tracey L., Zhou J., Fan M., Ng C.Y., Nathwani A.C., Stewart C.F., Pfeffer L.M., Davidoff A.M. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol. Cancer Ther. 2008, 7:3852-3858.
14. Jackson S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002, 23:687-696.
15. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., Ismail S., Stevens C., Meyn R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11:4912-4922.
16. Ahnesorg P., Smith P., Jackson S.P. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006, 124:301-313.
17. DuBois S.G., Matthay K.K. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl. Med. Biol. 2008, 35(Suppl. 1):S35-S48.
18. Ramalingam S.S., Parise R.A., Ramanathan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., Potter D.M., Argiris A.E., Zwiebel J.A., Egorin M.J., Belani C.P. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 2007, 13:3605-3610.
19. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. USA 2007, 104:19482-19487.
20. J.H. Lee, M.L. Choy, L. Ngo, S.S. Foster, P.A. Marks, Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair, Proc. Natl. Acad. Sci. USA 107, 14639-14644.
21. Masumoto H., Hawke D., Kobayashi R., Verreault A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 2005, 436:294-298.